As discussed in part one of this series, machine learning and AI have already been applied in several ways in the commercial life sciences -- yet there’s potential to do even more. In part two, Veeva Systems SVP of Commercial Strategy Paul Shawah and Aktana CEO David Ehrlich discuss what’s in store for this emerging technology and how commercial and medical teams can make the most of it.
Q&A with Veeva’s Paul Shawah and Aktana’s David Ehrlich – Part 1 In this two-part series, Veeva Systems SVP of Commercial Strategy Paul Shawah and Aktana CEO David Ehrlich discuss how to leverage machine learning and AI to optimize go-to-market strategy — both today and in the years to come. Part one below focuses on […]
Driven by customer success and innovation, Aktana introduces major product enhancements multiple times a year based on customer input, advancements in technology and data sciences, and industry changes. The latest enhancements to Aktana Decision Support center around improving control and visibility for customers, punctuated with a new integration with Salesforce Marketing Cloud.
Chief Science Officer Marc Cohen and the data science team at Aktana recently published their research in this area in The Journal of the Pharmaceutical Management Science Association, setting forth a successful machine learning approach for identifying message sequences that maximize open and click-through rates.
On the surface, it’s a pretty simple question: How do physicians want to be contacted by pharmaceutical companies? But as any pharma marketer knows, determining the ideal multichannel marketing mix is often anything but simple. QuintilesIMS explores this challenge of striking the right balance between digital contact and face-to-face detailing in their whitepaper, Channel Preference […]
MCM has become such a common topic in the pharma industry, it needs no explanation of the acronym. Its increasing importance is a natural outgrowth of the way information is consumed in our evolving world as well as more specific changes affecting the healthcare industry. Yet, most pharma companies struggle with how to launch programs […]